Referências

1. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G., Methods for the economic evaluation of health care programmes, (2005)
2. Stephens JM, Handke B, Doshi JA., International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research?, Comparative Effectiveness Research, 2012, pp. 29-44, (2012)
3. Guide to the processes of technology appraisal, (2018)
4. Angelis A, Lange A, Kanavos P., Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries, European Journal of Health Economics, 19, pp. 123-152, (2018)
5. Schrag D., The price tag on progress-Chemotherapy for colorectal cancer, New England Journal of Medicine, pp. 317-319, (2004)
6. Bach PB., Limits on medicare's ability to control rising spending on cancer drugs, New England Journal of Medicine, (2009)
7. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML., Projections of the cost of cancer care in the United States: 2010-2020, J Natl Cancer Inst, 103, pp. 117-128, (2011)
8. Burki TK., Rising cancer drug costs in the USA, The Lancet Oncology, 18, (2017)
9. Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR., Medical Care Costs Associated with Cancer Survivorship in the United States, Cancer Epidemiol Biomarkers Prev, 29, pp. 1304-1312, (2020)
10. Butler SS, Winkfield KM, Ahn C, Song Z, Dee EC, Mahal BA, Et al., Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017, Am Soc Clin Oncol Educ Book, 77, pp. 18-22, (2017)
11. Banta D., What is technology assessment?. International Journal of Technology Assessment in Health Care, pp. 7-9, (2009)
12. O'Rourke B, Oortwijn W, Schuller T., The new definition of health technology assessment: A milestone in international collaboration, International Journal of Technology Assessment in Health Care, pp. 1-4, (2020)
13. Oortwijn W, Mathijssen J, Banta D., The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries, Health Policy, 95, pp. 174-184, (2010)
14. Sampietro-Colom L, Lach K, Pasternack I, Wasserfallen JB, Cicchetti A, Marchetti M, Et al., GUIDING PRINCIPLES for GOOD PRACTICES in HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT UNITS, International Journal of Technology Assessment in Health Care, 31, pp. 457-465, (2016)
15. Cicchetti A, Iacopino V, Coretti S, Fiore A, Marchetti M, Sampietro-Colom L, Et al., Toward A Contingency Model for Hospital-Based Health Technology Assessment: Evidence from Adhophta Project, International Journal of Technology Assessment in Health Care, 34, pp. 205-211, (2018)
16. Tal O, Booch M, Bar-Yehuda S., Hospital staff perspectives towards health technology assessment: Data from a multidisciplinary survey, Health Research Policy and Systems, 17, (2019)
17. Angelis A, Kanavos P., Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework, Social Science and Medicine, 188, pp. 137-156, (2017)
18. Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Et al., Multiple criteria decision analysis for health care decision making-An introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force, Value in Health, 19, pp. 1-13, (2016)
19. Marsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kalo Z, Et al., Multiple Criteria Decision Analysis for Health Care Decision Making-Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, Value in Health, 19, pp. 125-137, (2016)
20. Thokala P, Duenas A., Multiple criteria decision analysis for health technology assessment, Value in Health, 15, pp. 1172-1181, (2012)
21. Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J., Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature, PharmacoEconomics, pp. 345-365, (2014)
22. Adunlin G, Diaby V, Xiao H., Application of multicriteria decision analysis in health care: A systematic review and bibliometric analysis, Health Expectations, 18, pp. 1894-1905, (2015)
23. Vorobiev P, Holownia M, Krasnova L., Multi-Criteria Decision Analysis (MCDA) and Its Alternatives in Health Technology Assessment, Journal of Health Policy and Outcomes Research, pp. 34-43, (2015)
24. Oliveira MD, Mataloto I, Kanavos P., Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art, European Journal of Health Economics, 20, pp. 891-918, (2019)
25. Martelli N, Hansen P, van den Brink H, Boudard A, Cordonnier AL, Devaux C, Et al., Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting, Journal of Biomedical Informatics, 59, pp. 201-208, (2016)
26. Angelis A, Kanavos P., Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment, Pharmacoeconomics, 34, pp. 435-446, (2016)
27. Mitton C, Donaldson C., Health care priority setting: Principles, practice and challenges, Cost Effectiveness and Resource Allocation, 2, (2004)
28. Daniels N., Accountability for reasonableness, British Medical Journal. BMJ, pp. 1300-1301, (2000)
29. Daniels N, Sabin JE., Accountability for reasonableness: an update, BMJ, 337, (2008)
30. Baltussen R, Jansen MP, Mikkelsen E, Tromp N, Hontelez J, Bijlmakers L, Et al., Priority setting for universal health coverage: We need evidence-informed deliberative processes, not just more evidence on cost-effectiveness, International Journal of Health Policy and Management, pp. 615-618, (2016)
31. Janssens R, Overbeeke E, Verswijvel L, Meeusen L, Coenegrachts C, Pauwels K, Et al., Patient involvement in the lifecycle of medicines according to Belgian stakeholders: The gap between theory and practice, Frontiers in Medicine, 5, (2018)
32. Campolina AG., Value-based medicine in oncology: the importance of perspective in the emerging value frameworks, Clinics, 73, (2018)
33. Wiffen P., Value or cost: Looking for the wider perspective, European Journal of Hospital Pharmacy, (2017)
34. Yu T, Enkh-Amgalan N, Zorigt G., Methods to perform systematic reviews of patient preferences: A literature survey, BMC Medical Research Methodology, 17, (2017)
35. Tervonen T, Pignatti F, Postmus D., From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs, Medical Decision Making, 39, pp. 879-885, (2019)
36. Baltussen R, Mikkelsen E, Tromp N, Hurtig AK, Byskov J, Olsen O, Et al., Balancing efficiency, equity and feasibility of HIV treatment in South Africa-development of programmatic guidance, Cost Effectiveness and Resource Allocation, 11, (2013)
37. Abe JM, Nakamatsu K, Akama S., Two applications of paraconsistent logical controller, Studies in Computational Intelligence, 142, pp. 249-254, (2008)
38. Abe JM, Akama S, Nakamatsu K., Introduction to Annotated Logics, (2015)
39. Mendelson Elliott, Introduction to mathematical logic, (2001)
40. de Carvalho FR., Paraconsistent logic in decision making: Paraconsistent decision method (PDM), Paraconsistent Intelligent Based-Systems: New Trends in the Applications of Paraconsistency, pp. 233-272, (2015)
41. da Costa NCA, Subrahmanian VS, Vago C., The Paraconsistent Logics PJ, Zeitschrift für Mathematische Logik und Grundlagen der Mathematik, 37, pp. 139-148, (1991)
42. (2018)
43. Hoff P, Diz M, Testa L., Manual de condutas em oncologia, (2019)
44. Nebuloni DR, Mak MP, Souza FH, Saragiotto DF, Julio T, de Castro G, Et al., Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis, Molecular and Clinical Oncology, 1, pp. 175-179, (2013)
45. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Et al., FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study, Journal of Clinical Oncology, 22, pp. 229-237, (2004)
46. Saltz LB, Cox J, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, New England Journal of Medicine, 343, pp. 905-914, (2000)
47. van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chien CRC, Makhson A, Et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, New England Journal of Medicine, 360, pp. 1408-1417, (2009)
48. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Et al., Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study, Journal of Clinical Oncology, 28, pp. 4697-4705, (2010)
49. Carvalho AC, Leal F, Sasse AD., Cost-effectiveness of cetuximab and panitumumab for chemotherapyrefractory metastatic colorectal cancer, PLoS ONE, 12, (2017)
50. Phillips LD, Phillips MC., Facilitated work groups: theory and practice, Journal of the Operational Research Society, 44, pp. 533-549, (1993)
51. Campolina AG, Suzumura EA, Hong QN, de Soarez PC., Multicriteria decision analysis in health care decision in oncology: a systematic review, Expert Review of Pharmacoeconomics & Outcomes Research, pp. 1-16, (2021)
52. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer, Technology Appraisal Guidance 118: National Institute for Health and Care Excellence, (2007)
53. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer, Technology Appraisal Guidance 212: National Institute for Health and Care Excellence, (2010)
54. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy, Technology Appraisal Guidance 242: National Institute for Health and Care Excellence, (2012)
55. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Et al., Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017, The Lancet, 392, pp. 1859-1922, (2018)
56. Carvalho FR, de Abe JM., A Paraconsistent Decision-Making Method, (2018)
57. Angelis A, Montibeller G, Hochhauser D, Kanavos P., Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting
58. Keeney RL, Raiffa H., Decisions with multiple objectives: preferences and value tradeoffs, (1993)
59. Drake JI, de Hart JCT, Monleon C, Toro W, Valentim J., Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016, Journal of Market Access & Health Policy, 5, (2017)
60. von Winterfeldt D, Edwards W., Decision analysis and behavioral research, (1986)
61. Fasolo B, Bana e Costa CA., Tailoring value elicitation to decision makers' numeracy and fluency: Expressing value judgments in numbers or words, Omega (United Kingdom), 44, pp. 83-90, (2014)
62. Broekhuizen H, Groothuis-Oudshoorn CGM, van Til JA, Hummel JM, IJzerman MJ., A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions, PharmacoEconomics, pp. 445-455, (2015)
63. Montibeller G, von Winterfeldt D., Cognitive and Motivational Biases in Decision and Risk Analysis, Risk Analysis, 35, pp. 1230-1251, (2015)